Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preclinical evaluation of a fluorine-18-labeled indocyanine green analog for PET imaging of hepatic function.

EJNMMI radiopharmacy and chemistry·2026
Same author

In vitro radionuclide labeling characteristics of blenderized tube feeds for quantitative gastric motility assessment.

JPGN reports·2025
Same author

Potential of Magnetic Hyperthermia to Stimulate Localized Immune Activation.

Small (Weinheim an der Bergstrasse, Germany)·2021
Same author

SNMMI Mid-Winter and ACNM Annual Meeting.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2021
Same author

SNMMI Diversity, Equity, and Inclusion Task Force Statement.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2020
Same author

In vivo detection of antigen-specific CD8<sup>+</sup> T cells by immuno-positron emission tomography.

Nature methods·2020
Same journal

Flavonoid nanoformulations for cutaneous administration: overcoming delivery barriers for targeted therapeutics and bioavailability enhancement.

Therapeutic delivery·2026
Same journal

Optimization of nanoemulsion formulations of <i>Piper sarmentosum</i> for topical application in skin cancer.

Therapeutic delivery·2026
Same journal

An evaluation of aripiprazole long-acting injectable monthly and bimonthly in the maintenance treatment of bipolar I disorder.

Therapeutic delivery·2026
Same journal

A decision-support workflow for the selection of mathematical models in drug dissolution and release studies.

Therapeutic delivery·2026
Same journal

Ternary co-encapsulation in electrospun PVA fibers: release kinetics and mechanisms.

Therapeutic delivery·2026
Same journal

Damp scalp application enhances follicular delivery of dutasteride loaded in liposomes compared to dry scalp.

Therapeutic delivery·2026
See all related articles

Related Experiment Video

Updated: May 20, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Radioimmunotherapy: optimizing delivery to solid tumors.

Vineeth Rajkumar1, Jason L Dearling, Alan Packard

  • 1UCL Cancer Institute, University College London, 72 Huntley St., London WCIE 6BT, UK.

Therapeutic Delivery
|July 27, 2012
PubMed
Summary
This summary is machine-generated.

Radioimmunotherapy (RIT) optimizes solid tumor treatment by studying tumor microenvironment interactions in preclinical models. This translational research aims to improve RIT efficacy for colorectal adenocarcinoma and other solid tumors.

More Related Videos

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

Related Experiment Videos

Last Updated: May 20, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

Area of Science:

  • Oncology
  • Immunotherapy
  • Radiochemistry

Background:

  • Radioimmunotherapy (RIT) utilizes monoclonal antibodies to target tumor cells with cytotoxic radionuclides.
  • RIT is effective for hematologic cancers but shows limited prolonged effects in solid tumors.
  • Solid tumor RIT requires optimization to overcome challenges in the tumor microenvironment.

Purpose of the Study:

  • To develop a translational pipeline for optimizing RIT in solid tumors.
  • To investigate tumor microenvironment interactions with RIT in colorectal adenocarcinoma models.
  • To test novel therapeutic strategies for enhancing RIT efficacy.

Main Methods:

  • Development of a bench-to-bedside translational research pipeline.
  • Utilized preclinical models of colorectal adenocarcinoma.
  • Studied reciprocal interactions between tumor microenvironment elements and RIT.

Main Results:

  • Preclinical models allowed detailed study of RIT and tumor microenvironment interplay.
  • Novel therapeutic strategies were identified and tested.
  • Findings facilitated the design of new clinical trials.

Conclusions:

  • A translational pipeline can optimize RIT for solid tumors.
  • Understanding tumor microenvironment interactions is crucial for RIT success.
  • This research supports improved RIT strategies in clinical settings.